Zogenix, Inc.
5959 Horton St 5th floor
Emeryville
California
94608
United States
Website: http://www.zogenix.com/
Email: info@zogenix.com
335 articles about Zogenix, Inc.
-
The FDA has a full PDUFA calendar for the second half of March for New Drug Applications and Biologics License Applications. Here's a look.
-
UCB Completes Acquisition of Zogenix, Inc.
3/7/2022
UCB (Euronext: UCB) today announced the successful completion of the previously announced transaction to acquire Zogenix (NASDAQ: ZGNX) for US$ 26.00 per share plus a milestone-based contingent value right for a potential cash payment of US$ 2.00 per share.
-
Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022
3/4/2022
Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that new data from the company’s research and development program for FINTEPLA® (fenfluramine) in Lennox Gastaut syndrome (LGS) will be presented at the hybrid American Academy of Neurology (AAN) Annual Meeting 2022.
-
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
2/28/2022
Zogenix, a global biopharmaceutical company developing and rare disease therapies, provided a corporate update and announced financial results for the fourth quarter and full-year ended December 31, 2021.
-
Zogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial Diseases
2/15/2022
Zogenix (NASDAQ: ZGNX), today announced that the company is sponsoring a new no-cost genetic testing program, the United Mitochondrial Disease Foundation (UMDF) Pilot Genetic Testing Project, in partnership with UMDF and Probably Genetic, to help patients obtain a confirmed genetic diagnosis of mitochondrial disease.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
UCB to acquire Zogenix
1/19/2022
Regulated information – Inside information – UCB and Zogenix announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.
-
UCB has announced that it is acquiring Zogenix as part of plans to expand its reach into commercializing and developing treatments for rare diseases.
-
Zogenix Submits New Drug Application for FINTEPLA® (Fenfluramine) in Japan for the Treatment of Epileptic Seizures Associated with Dravet Syndrome
12/21/2021
Zogenix, a global biopharmaceutical company specializing in rare disease therapies, announced that it has submitted a New Drug Application (J-NDA) to the Japanese Ministry of Health, Labour & Welfare (MHLW) for the marketing approval of FINTEPLA® (fenfluramine) for the treatment of epileptic seizures associated with Dravet syndrome in Japan.
-
Zogenix Submits Type II Variation Application to the European Medicines Agency (EMA) to Expand the Use of FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome
12/20/2021
Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it has submitted its Type II Variation Market Authorization Application to the European Medicines Agency (EMA) for FINTEPLA® for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a highly treatment-resistant form of childhood-onset epilepsy.
-
Zogenix Reports Granting of Inducement Awards - Dec 16, 2021
12/16/2021
Zogenix announced that the compensation committee of the company’s board of directors granted inducement awards to nine new non-executive employees.
-
Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES 2021Data add to the growing body of evidence supporting the efficacy and safety profile of FINTEPLA for the treatment of Dravet syndrome
12/2/2021
Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it will present new FINTEPLA® (fenfluramine) data from eight abstracts at the American Epilepsy Society (AES) Annual Meeting, taking place from December 3-7, 2021, in Chicago, IL.
-
Zogenix Announces U.S. FDA Acceptance for Priority Review of Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures
12/1/2021
Zogenix today announced the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review to the company’s supplemental New Drug Application (sNDA) for the use of FINTEPLA ® for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).
-
Zogenix Reports Granting of Inducement Awards - Nov 17, 2021
11/17/2021
Zogenix announced that the compensation committee of the company’s board of directors granted inducement awards to thirteen new non-executive employees.
-
Zogenix to Participate in Two Upcoming Investor Conferences - Nov 11, 2021
11/11/2021
Zogenix, a global biopharmaceutical company developing rare disease therapies, announced that members of its management team will participate in fireside chats at two upcoming investor conferences: the Stifel 2021 Virtual Healthcare Conference and Guggenheim Virtual 3rd Annual Neuro/Immunology Conference.
-
Zogenix Provides Corporate Update and Reports Third Quarter 2021 Financial Results
11/4/2021
Zogenix, a global biopharmaceutical company developing rare disease therapies, announced financial results for the three and nine months ended September 30, 2021, and provided a corporate update.
-
Zogenix to Host Key Opinion Leader Webinar on Thymidine Kinase 2 Deficiency and MT-1621 Webinar on Monday, November 8th, at 12:00 PM ET
11/1/2021
Zogenix today announced that it will host a key opinion leader (KOL) webinar on thymidine kinase 2 deficiency (TK2d) and MT-1621 on Monday, November 8, 2021, at 12:00 PM Eastern Time.
-
Zogenix to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4
10/21/2021
Zogenix today announced data that it will report its financial results for the third quarter ended September 30, 2021 and host a corporate update conference call and webcast after the market close on Thursday, November 4, 2021, at 4:30 PM Eastern Time.
-
It was a busy week for clinical trial news. Here’s a look.
-
Zogenix Submits Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome
9/28/2021
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has submitted a supplemental New Drug Application (sNDA) for FINTEPLA® (fenfluramine) for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) to the U.S. Food and Drug Administration (FDA).